-->

Tag: KRAS G12C

Home / KRAS G12C

Categories

Sotorasib receives accelerated approval from the FDA for KRAS G12C mutant NSCLC

August 2021: The FDA granted accelerated approval to sotorasib (LumakrasTM, Amgen, Inc.), a RAS GTPase family inhibitor, for adult patients with KRAS G12C mutated locally advanced or metastatic non-sm...
kras-g12c

The FDA has approved the first targeted therapy for a lung cancer mutation that was previously thought to be drug-resistant

August 20, 2021: Recently in May, 2021 Lumakras (sotorasib) was approved by the US Food and Drug Administration as the first treatment for adult patients with non-small cell lung cancer who have under...
kras-g12c

Scan the code